Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

  • Technology appraisal guidance
  • TA170
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield:

  • Stevenson M, Scope A, Holmes M et al. Rivaroxaban for the prevention of venous thromboembolism, December 2008

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Manufacturers, or sponsors, were also invited to make written submissions. Professional or specialist and patient or carer groups and other consultees gave their expert views on rivaroxaban by providing a written statement to the Committee. Manufacturers, or sponsors, professional or specialist and patient or carer groups and other consultees have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Bayer HealthCare (rivaroxaban)

Professional or specialist and patient or carer groups:

  • Anticoagulation Europe

  • British Association for Surgery of the Knee

  • British Orthopaedic Association

  • British Society for Haematology

  • British Society for Haemostasis and Thrombosis

  • British Thoracic Society

  • DVT Awareness Campaign

  • Lifeblood: The Thrombosis Charity

  • Royal College of Nursing

  • Royal College of Pathologists

Other consultees:

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline (fondaparinux sodium)

  • Leo Laboratories (tinzaparin sodium)

  • National Collaborating Centre for Acute Care

  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

  • Pfizer Ltd (dalteparin sodium)

  • Research Institute for the Care of the Elderly

  • Sanofi-Aventis Ltd (enoxaparin sodium)

  • School of Health and Related Research (ScHARR), University of Sheffield

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on rivaroxaban by providing oral evidence to the Committee:

  • Annya Stephens – Boal, Executive Officer, nominated by Lifeblood: The Thrombosis Charity – patient expert

  • Eve Knight, Chief Executive, nominated by AntiCoagulation Europe – patient expert

  • Colin Howie, Consultant Orthopaedic Surgeon, nominated by the British Orthopaedic Association – clinical specialist

  • Professor Mike Laffan, Professor of Haemostasis and Thrombosis, nominated by the British Society for Haematology – clinical specialist